<DOC>
	<DOCNO>NCT01328756</DOCNO>
	<brief_summary>While Lisdexamfetamine Dimesylate ( SPD489 ) clinical program study efficacy , safety , tolerability SPD489 treat core symptom ADHD child adolescent age 6-17 year adult age 18-55 year , majority study short duration - 8 week . A number long-term study undertake ( 1 year ) confirm safety ongoing efficacy patient population . In order run study investigational medication within Poland study change Phase 3 rather Phase 4 study country . Please note study number remain SPD489-404 . Study SPD489-404 design evaluate long-term effect SPD489 child adolescents 2-year treatment period .</brief_summary>
	<brief_title>Lisdexamfetamine Dimesylate 2-year Safety Study Children Adolescents With Attention-Deficit/Hyperactivity Disorder ( ADHD )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<criteria>For subject participate another SPD489 study ( SPD489317 , SPD489325 , SPD489 326 ) : Subject male female age 617 year . Subject participate SPD489317 , complete 9 week treatment , complete 1 week posttreatment safety followup visit . For subject participate another SPD489 study : Subject male female age 617 year . Subject must meet DSMIVTR criterion primary diagnosis ADHD base detailed psychiatric evaluation . For subject : Subject Baseline ADHDRSIV total score great equal 28 . Subject , female childbearing potential ( FOCP ) , must negative serum beta Human Chorionic Gonadotropin ( HCG ) pregnancy test , negative urine pregnancy test Baseline , nonlactating agree comply applicable contraceptive requirement protocol . Subject parent/LAR willing able comply test requirement define , include oversight morning dosing . Specifically , parent/LAR must available upon awaken , approximately 7:00 AM , dispense dose Investigational Product duration study . Subject age great equal 18 year systolic blood pressure less equal 139 mmHg diastolic blood pressure less equal 89 mmHg . Subject able swallow capsule . For subject participate another SPD489 study ( SPD489317 , SPD489325 , SPD489 326 ) : Subject terminate previous SPD489 study ( SPD489325 SPD489 326 ) protocol nonadherence and/or subject noncompliance and/or experience medicationrelated SAE AE result termination previous study . Subject experience clinically significant AEs prior SPD489 study ( SPD489 317 , SPD489325 , SPD489326 ) , opinion Investigator , would preclude exposure SPD489 . For subject : Subject 's symptom wellcontrolled currently prescribe ADHD medication acceptable tolerability . Subject positive urine drug result Screening . Subject current , control ( require restrict medication ) uncontrolled , comorbid psychiatric diagnosis significant symptom severe comorbid Axis II disorder severe Axis I disorder ( Post Traumatic Stress Disorder , psychosis , bipolar illness , pervasive developmental disorder , severe obsessive compulsive disorder , severe depressive severe anxiety disorder ) symptomatic manifestation , agitate state , mark anxiety , tension . Subject take another Investigational Product take part clinical study exception prior SPD489 study ( SPD489317 , SPD489 325 , SPD489 326 ) within 30 day prior Screening . Subject weigh less 22.7 kg ( 50 lb ) . Subject significantly overweight . Subject conduct disorder . Oppositional defiant disorder exclusionary . Subject concurrent chronic acute illness ( severe allergic rhinitis infectious process require antibiotic ) , disability , condition might confound result safety assessment conduct study might increase risk subject . Subject currently consider suicide risk opinion Investigator , previously make suicide attempt , prior history , currently demonstrate active suicidal ideation . Subjects intermittent passive suicidal ideation necessarily exclude base assessment Investigator Subject glaucoma . Subject current abnormal thyroid function , define abnormal thyroid stimulate hormone ( TSH ) thyroxine ( T4 ) . Treatment stable dose thyroid medication least 3 month permit . Subject clinically significant ECG abnormality . Subject clinically significant laboratory abnormality . Subject document allergy , hypersensitivity , intolerance active ingredient excipients SPD489 . Subject recent history ( within past 6 month ) suspect substance abuse dependence disorder ( exclude nicotine ) accordance DSMIVTR criterion . Subject history seizure ( infantile febrile seizure ) , chronic current tic disorder , current diagnosis Tourette 's Disorder , know family history Tourette 's Disorder . Subject history tic judge Investigator exclusionary . Subject known history symptomatic cardiovascular cerebrovascular disease , advanced arteriosclerosis , structural cardiac abnormality , cardiomyopathy , serious heart rhythm abnormality , coronary artery disease , serious cardiac problem may place increased vulnerability sympathomimetic effect stimulant drug . Subject know family history sudden cardiac death ventricular arrhythmia . Subject medical condition , ADHD , require treatment medication central nervous system effect and/or affect performance . Stable use anticholinergic theophylline bronchodilator exclusionary .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>ADHD</keyword>
</DOC>